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A RANDOMISED, OPENLABEL COMPARATIVE STUDY OF 
HYDROXYCHLOROQUINE WITH BETAMETHASONE ORAL MINIPULSE IN 
PATIENTS WITH ALOPECIA AREATA 
 
AUTHORS: Dr. J.Jeyasudha, Dr. K.M.Sudha, M.D, Institute of Pharmacology, Madras 
Medical College. 
                                                    ABSTRACT 
AIM: 
To compare the efficacy and tolerability of Hydroxychloroquine with standard 
Betamethasone oral minipulse in the management of Alopecia areata. 
METHODOLOGY: 
This was an open label, comparative, randomized, prospective study.  60 patients with 
Alopecia areata, were included and randomized into two groups of 30(male-18, female-12) 
each. Control group received Tab. Betamethasone 5mg/day on two consecutive days of 
week for 12 weeks and Study group received Tab. Hydroxychloroquine 400 mg/day for a 
period of 12 weeks. They were followed-up for another 12weeks. Scale of Alopecia Tool 
score, Dermatology Life Quality Index and Global assessment were used to assess the 
severity of hair loss, impact on quality of life and treatment outcome respectively. The tests 
were done every 4 weeks and lab investigations were done at baseline and at the end of 12 
weeks.  
RESULTS: 
94 patients were screened and 60 patients were included. All patients completed the study. 
At the end of 12 weeks, there was a statistically significant reduction in SALT and DLQI 
scores in both control and Study groups. But during the follow up period, the study group 
showed an increase in the scores compared to the control group. Relapses were more in the 
study group. No significant difference in the incidence of adverse events was noted 
between the two groups. No differences in laboratory parameters were observed from 
baseline to 12 weeks.  
 CONCLUSION: 
Hydroxychloroquine 400 mg/day is efficacious and safe in the management of Alopecia 
areata. 
KEY WORDS: 
Betamethasone oral minipulse, Hydroxychloroquine, Alopecia areata. 
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INTRODUCTION 
 
                         Alopecia areata is a chronic disease which affects the hair follicle and the 
nails. Both genetic and environmental factors play a role in the pathogenesis of the disease. 
Alopecia areata is associated with atopy and other autoimmune diseases like myxoedema 
and pernicious anaemia.1 Stress is also a known precipitating factor.  
                       The onset of the disease usually occurs in the second decade, although any 
age may be affected. Both males and females are equally affected. The usual presentation 
is an asymptomatic patch of loss of hair, which may occur on the scalp or any other hairy 
part of the body. Eyebrows and eyelashes may be involved. Severe cases are characterized 
by loss of hair on the entire scalp or even the whole of the body2 .The extensive hairloss 
gives rise to poor self-esteem and impairment of social and recreational activities. It 
eventually leads to considerable anxiety and depression in the affected patients.  
                      Histopathology of Alopecia areata shows it to be a T cell mediated 
autoimmune disorder with antibodies directed against unknown antigens in the hair 
follicle.3This autoimmune process truncates the anagen phase of the hair follicle and diverts 
it to telogen phase. 34–50% of patients will recover within 1 year, whereas 14–25% have 
progressive disease, from which full recovery is unusual (less than 10%) 4. In mild cases, 
a wait and watch policy may be adopted whereas in very severe and progressive disease, 
patient should be counselled about using a cosmetic camouflage like a wig. 
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                    Treatment of this condition is mainly aimed at arresting the autoimmune 
process. This is mainly done by topical agents which act by diverting the inflammatory 
infiltrate away from the hair follicle or by using systemic drugs which suppress the 
immunity like steroids or other immunosuppressants. But all these modalities of treatment 
are associated with significant adverse effects in the long term. This makes the patients 
poorly compliant to therapy and worsens the outcome of the disease. Hence there is a search 
for a therapeutic agent which alters the immune function without causing major side 
effects. 
                      Hydroxychloroquine is an antimalarial drug, with T cell modulating function. 
It is used with varying degrees of success in Rheumatoid arthritis5 Systemic Lupus 
Erythematosus and skin conditions like frontal fibrosing alopecia, pseudopelade of Brocq 
and lichen planopilaris.6 It is also used as a systemic sunscreen in photodermatoses. There 
are case reports of successful use of hydroxychloroquine in severe and treatment resistant 
cases of Alopecia areata from the western countries, but no data are available from India.7 
                        Hence this study is undertaken to assess the safety and efficacy of 
Hydroxychloroquine in Alopecia areata and its tolerability in Indian patients. It is 
compared with Betamethasone Oral Minipulse (OMP) therapy which is the standard 
treatment given in this condition.   
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REVIEW OF LITERATURE 
 
                          Alopecia areata is an inflammatory disease of chronic nature mainly 
affecting the hair follicle and the nails. It was first described by Cornelius Celsus, and the 
term was coined by Sauvages .The term alopecia means ‘fox mange’, denoting loss of hair. 
The incidence is 0.1–0.2% with a 1.7% lifetime risk of developing the disease. In India, 
the incidence of the disease is 0.7% in the dermatology Outpatient Department.8 It occurs 
at all ages. Males and females are equally affected. Both genetic and environmental factors 
play a role in causation of this condition. 
GENETIC FACTORS: 
                            10 to 20% of patients with alopecia areata give a positive family history. 
There is a 55% concordance in monozygotic twins and no concordance in dizygotic twins. 
The inheritance of Alopecia areata is polygenic. It is strongly associated with genes of the 
major histocompatibility complex (MHC), particularly the Class II alleles HLA-
DQB1*0301 and HLA-DRB1*11049,10. The susceptibility to Alopecia areata is determined 
on chromosomes 10, 16 and 18.  
ENVIRONMENTAL FACTORS: 
                        Evidence suggests that in genetically susceptible individuals, environmental 
factors like trauma, stress, certain diets, vaccination and infection precipitate the hair loss. 
11 
 
Especially, psychological stress is recognized as a triggering factor by many patients. 
These factors trigger the onset of the disease, but have no role in the final outcome and 
prognosis.11  
ANATOMY OF THE HAIR: 
                                  In humans, there are three types of hair- Lanugo hair, which is a 
prenatal coat of fine, soft, unmedullated and unpigmented hair, Vellus hair, which is soft, 
short , unmedullated, unpigmented hair; and Terminal hair, which is longer, coarser, 
medullated and pigmented. Before puberty, terminal hair is normally seen in the scalp, 
eyebrows and eyelashes. After puberty, secondary sexual ‘terminal’ hair develops from 
vellus hair in the axillary and pubic areas in response to androgens. The average density of 
scalp hairs is 1135/cm2 for newborn, 615/cm2 for 20-30 years, 485/cm2 for 30-50 years and 
435/cm2 for 70-80 years. Asians and African Americans have a lower than average scalp 
hair density. 
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                                               Anatomy of hair follicle 
                    The hair follicle is divided into 4 parts- the bulb, the Suprabulb region, the 
Isthmus and the Infundibulum.  
Bulb- The bulb includes the dermal papilla and the hair matrix. The dermal papilla consists 
of mesenchymal cells surrounded by ground substance which is rich in acid 
mucopolysaccharides (AMPs). The papilla is responsible for hair growth. The lower part 
of the dermal papilla is connected to the fibrous root sheath. The hair matrix gives rise to 
the hair shaft and the internal root sheath. In individuals with dark hair, melanin is found 
within the melanophages of the dermal papilla. Melanocytes can be found between the 
basal cells of the hair matrix. Melanin is transferred from these melanocytes into the cells 
that make up the hair shaft and it is responsible for giving color to the hair. 
Suprabulb region- The suprabulb region extends from the bulb to the isthmus and consists 
of hair shaft, IRS, ORS, vitreous layer, and fibrous root sheath. 
Isthmus- The isthmus extends from the attachment of the arrector pili muscle (bulge 
region) to the entrance of the sebaceous gland duct. 
 Infundibulum- The infundibulum is the upper portion of the hair follicle, above the entry 
of the sebaceous duct. It is lined by epidermis. 
The cut section of the hair follicle shows the following layers from within to outside- 
Hair shaft-The hair shaft consists of 3 layers. The outermost layer of the hair shaft is the 
cuticle which consists of overlapping cells arranged like shingles. The middle layer is the 
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hair cortex which constitutes the bulk of the hair and consists of cells that keratinize 
gradually as they move upward from the hair matrix. The innermost layer, medulla is 
difficult to visualize as it is discontinuous and absent in many regions. 
Inner root sheath - The inner root sheath (IRS) is closely apposed to the hair shaft and 
consists of 3 concentric cell layers.    
 Outer root sheath- The outer root sheath (ORS) covers the IRS. It extends upward from 
the matrix cells at the lower end of the hair bulb to the point of entrance of the sebaceous 
duct. The ORS is thinnest at the level of the bulb and thickest in the middle portion of the 
hair follicle. It does not keratinize below the level of the isthmus 
Fibrous root sheath- The fibrous root sheath is the outermost layer of the hair follicle and 
consists of thickened collagen bundles which coat the hair follicle. The root sheath is 
continuous with the dermal papilla at its lower end and with the papillary dermis above it.   
THE HAIR CYCLE:    
                         The hair goes through three phases of development known as the anagen, 
catagen, and telogen phases. Each strand of hair on the human body is at its own stage of 
development. At any given time all three phases of hair development may be seen in the 
scalp.  The anagen phase is the growth phase of hair. The longer the hair is in the anagen 
phase, the longer it grows. At any given time, about 85% of the hairs on scalp are in the 
anagen phase. The catagen phase is also known as the transitional phase .This phase lasts 
about two weeks. The hair follicle shrinks due to disintegration, the papilla detaches and 
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cuts the hair strand off from its nourishing blood supply. Ultimately, the follicle shrinks to 
1/6 its original length, causing the hair shaft to be pushed upward. During the telogen or 
resting phase, the follicle remains dormant for 1–4 months. 10-15% of the hairs on one's 
scalp are in this phase of growth at any given time. Then the hair base breaks free from the 
root and the hair is shed. A new hair shaft begins to emerge within two weeks.                            
IMMUNOLOGY OF ALOPECIA AREATA:    
Association with other autoimmune disorders:                                 
                            Alopecia areata is associated with other autoimmune disorders like 
myxoedema and pernicious anaemia. Circulating autoantibodies to hair follicle tissue have 
been found in patients, but their role in pathogenesis is not clear. Patients have an increased 
frequency of circulating organ-specific autoantibodies compared with normal subjects. 
Nonspecific abnormalities in peripheral T-cells have also been noted. Gilhar et al first 
showed that hair growth recovered in bald skin transplanted on to athymic nude mice12. 
They also induced alopecia in grafted skin by injecting autologous T cells incubated with 
hair follicle extracts and antigen presenting cells. 
 
Collapse of Hair follicle Immune Privilege41 
                        Certain sites of the body are specially protected from immune reactions, 
which is termed as Immune privilege. The sites which enjoy immune privilege include 
anterior eye chamber, parts of testis and ovaries, adrenal cortex, parts of the central nervous 
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system enclosed by the blood-brain barrier and the placenta. The immunosuppressive 
milieu prevalent at these sites protects the organs from deleterious immune reactions and 
loss of function. For example a dangerous immune reaction in the anterior chamber of eye 
can cause blindness. The anagen hair follicle enjoys Immune privilege due to-  
 Absent or barely detectable MHC class I in the outer root sheath and matrix. 
 Hair follicular melanocytes of the human anagen scalp are MHC class I-negative.     
 Downregulation of the MHC class I pathway-related molecules  2-microglobulin 
and transportation of antigen processing-2 (TAP-2).  
 Downregulation of interferon regulatory factor-1 expression.    
 Upregulation of immunosuppressive factors like TGF- 1 and TGF- 2, ACTH, α-
MSH. 
 Absence of MHC class II+ or NLDC-145+ Langerhans cells.    
 Sparse distribution of NK cells and CD4+ and CD8+ T cells.     
 Absence of lymphatics.  
                       HFIP is present during anagen but is lost during the telogen and catagen 
phases of the hair cycle. Collapse of HFIP contributes to the development of AA, in which 
pigment-producing anagen hair bulbs are attacked by inflammatory cells. Infections, 
trauma and stress are known to cause increased production of Interferon-gamma. Interferon 
(IFN)-γ is a key cytokine implicated in the pathogenesis of AA and it upregulates MHC 
class I expression in hair follicles. 
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                      CD8+ T cells react to autoantigens by binding to MHC class I molecules. 
These CD8+ T cells accumulate within and around the anagen hair bulbs and initiate the 
autoimmune process. 
CLINICAL FEATURES:  
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                       Alopecia areata usually presents at any age and equally affects both sexes. 
Early onset and positive family history indicate a severe and progressive disease. Ikeda 
classified Alopecia areata as follows- 
Atopic type: It begins early in childhood and most commonly (30-75%) progresses to 
Alopecia Totalis (AT). 
Autoimmune type: It is seen in middle-aged groups and associated with other autoimmune 
diseases like diabetes mellitus. 10-50% progress to AT. 
Prehypertensive type: This is seen in young adults whose parents have hypertension. 
Common type: It affects adults aged 20-40 years and AT develops in 5-15% of cases. 
 
              
      Alopecia areata                                                    Nail changes          
 
18 
 
             The initial lesion is a circumscribed, totally bald, smooth patch on the scalp (90%) 
or any other part of the body (10%). It is asymptomatic and usually noticed by a hairdresser 
or friend.  The patches are devoid of redness, itching, scaling or follicular changes. 
Individual patches may expand circumferentially, coalesce and form a large patch. 
Characteristic 'exclamatory mark hairs' are seen either within or at the border of the patches. 
These are fractured and short hairs with broad distal ends and proximal tapering close to 
scalp. They are due to hair follicle damage in anagen followed by a rapid transformation 
to telogen. The presence of exclamatory hairs at the border and the hair pull test with 6 or 
more hairs from the periphery indicates that the disease may be active. Regrowth is fine 
and unpigmented initially, but the hairs gradually resume their normal calibre and colour.  
 
       
               Oophiasis                                              Linear type            
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                           In patients with mixture of dark and grey hairs, the disease selectively 
affects the dark hairs leading to their loss. The unpigmented hairs are spared, which the 
patients describe as ‘going grey overnight’. Although the white hairs are spared initially, 
they are not immune and are affected as the disease becomes progressive.13 The various 
terms used to describe the patches of alopecia areata are as follows. 
ALOPECIA TOTALIS- involves the entire scalp and some body hair such as eyebrows, 
eyelashes, beard, axillary hair and pubic hair. 
ALOPECIA UNIVERSALIS- involves loss of total scalp and body hair. 
OOPHIASIS- means ‘snake like.’ It is a band-like hair loss along the posterior occipital 
and temporal margins. 
SISAIPHO- This is also known as oophiasis inversus and  presents with alopecia involving 
the frontal, temporal, and parietal scalp but spares hair along the scalp periphery. This 
should be differentiated from Androgenetic alopecia. 
RETICULAR –The hair loss occurs in a reticular or net like pattern. 
PERINEVOID- alopecia patches are seen around the nevi. 
LINEAR- hair loss occurs in a linear distribution. 
DERMOSCOPY:  
                          Dermoscopy is an easy bedside technique used to observe the severity of 
hair loss. It can also give a clue to the cause of hair loss. Dermoscopy done on the scalp 
and hair is known as Trichoscopy. Yellow dots, black dots, broken hairs, tapering hair 
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(exclamation marks), and short vellus hairs are the characteristic dermoscopic features of 
Alopecia areata.14,15 Inui et al. described coudability hairs which are normal looking hairs, 
but show a thinning and kinking in the proximal aspect.  Presence of black dots, broken 
hair, and tapering hair suggest active disease. There is no single feature in dermoscopy 
which is diagnostic of Alopecia areata, but a combination of features help to make a proper 
clinical diagnosis. 
 
NAIL CHANGES: 
                         Nail changes are seen in 10-15% of cases of alopecia areata. Nail changes 
may precede or follow the hair loss, and they may be observed in one or most nails. 
Sometimes they may be the reason for the patient approaching a dermatologist. The most 
common finding is a fine, stippled pitting of the nails. Alopecia areata may also cause 
roughening of the nail plate (trachyonychia) or a non-specific dystrophy. The other changes 
include Punctate leukonychia, Beau's lines, onychomadesis, mottled and red lunulae.16 
Presence of nail changes indicates a severe disease. 
 
EYE CHANGES:  
                          Punctate lens opacities, early cataracts, and fundus abnormalities may 
occur in 40% to 50% of patients with Alopecia areata.17 
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HISTOPATHOLOGY: 
In early stages, the anagen follicles characteristically show a perifollicular and 
intrafollicular inflammatory cell infiltrate composed of activated CD4 T lymphocytes and 
an admixture of macrophages and Langerhans’ cells. This is termed as ‘Swarm of bees’ 
appearance. The infiltrate is seen mainly around the isthmus of the hair follicle which is 
the site of hair follicle stem cells.      
 
                                Histopathology of Alopecia areata     
                                
 Swarm of bees appearance                           Lymphocytes within the follicle 
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                     Later, anagen follicles are precipitated into telogen. Follicles re-enter anagen 
but are unable to progress beyond the Anagen 3–4 stage. They then return prematurely to 
telogen. These cycles of anagen- telogen continue for as long as the disease is active. In 
chronic cases, there is miniaturization of hair follicle, which loses the hair shaft but may 
contain remnants of inner root sheath.  
PSYCHIATRIC MORBIDITY: 
                        AA is associated with considerable psychiatric morbidity in the form of 
anxiety and depression. Patchy loss of hair leads to poor self-esteem and impairment in the 
Quality of Life as evidenced by reduced sports and recreational activities and diminished 
sexual drive.18 Colón et al. reported that 74% of patients were given one or more lifetime 
psychiatric diagnoses based on structured psychiatric interviews. The lifetime prevalence 
rates of major depression (39%) and generalized anxiety disorder (39%) were high. This 
shows that patients with AA have a poor Quality of Life (QOL) and are at an increased risk 
for developing anxiety and depression. 
 
DISEASES ASSOCIATED WITH ALOPECIA AREATA:  
                                  Alopecia areata is associated with atopy in 10-22% cases. In these 
patients, the disease characteristically presents early, is more severe and resistant to 
treatment. The chance of developing Alopecia Totalis is high (30-75%). It is also seen in 
association with autoimmune thyroiditis in 8-28% of cases1. Other autoimmune disorders 
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like vitiligo, Addison's disease, Autoimmune polyglandular syndrome are found with 
Alopecia areata. These patients are more likely to progress to Alopecia Totalis (10-50%). 
Sharma et al. has reported that vitiligo in family members is an independent risk factor for 
developing severe forms of alopecia.19.Systemic lupus erythematosus, celiac disease, 
ulcerative colitis, multiple sclerosis are the other associations observed, although the cause 
for the disease co-occurrence is not known. There is an increased incidence of type I 
diabetes in the family members of AA, but the AA patients themselves have reduced 
incidence20.  
 
DIFFERENTIAL DIAGNOSIS: 
                              Depending on the age, duration of illness and other features, several 
other conditions should be considered before making a diagnosis. Itchy scaly areas of hair 
loss in a child may suggest Tinea capitis, while a psychiatric patient with hair loss at 
accessible sites should prompt a diagnosis of Trichotillomania. Hair loss in secondary 
syphilis may also mimic Alopecia areata. Sudden acute hair loss may be due to Telogen 
effluvium and in an adult patient with a large patch over the vertex, a diagnosis of 
Androgenetic alopecia should be considered. Other common conditions that resemble AA 
include traction alopecia and Pressure alopecia. When there is doubt, a scalp biopsy is the 
best aid in diagnosis.   
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COURSE OF THE DISEASE: 
                              Many cases show a spontaneous regrowth of hair. And some of the 
treated patients may experience a relapse. For a few patients, the disease runs a remitting 
relapsing course over several years. A small proportion of patients do not show regrowth 
even after years of treatment.  Poor prognosis is indicated in younger age of onset, positive 
family history, presence of atopy and autoimmune disorders, disease duration more than 
one year, severe disease with nail changes, oophiasis pattern hair loss, Alopecia Totalis 
and Alopecia Universalis.5-10% of patients may progress to total hair loss. 
TREATMENT: 
                            Treatment of Alopecia areata ranges from simple reassurance for mild 
cases, topical agents, systemic therapy to cosmetic camouflage for severe treatment 
resistant cases. 
TOPICAL AGENTS: 
                            These are broadly classified as- 
1) Topical Irritants 
2) Topical immunomodulators - steroids/ calcineurin inhibitors, 
3) Topical Minoxidil   
4) Topical contact sensitisers. 
5) Other topical agents. 
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TOPICAL IRRITANTS 
               These agents cause irritation, a local inflammatory reaction and divert the T 
lymphocytic infiltrate away from the hair follicle.  This effect causes regrowth of hair in 
the patch. The various topical irritants used include- 
o Anthralin 
o Dithranol 
o Salicylic acid 
o Capsaicin gel 
o Garlic juice 
o Onion juice 
o Tincture iodine 
o Bexarotene 1% gel 
o Tretinoin 0.05% ointment 
o Azelaic acid 
o Liquid nitrogen cryotherapy. 
                 The efficacy of this treatment is variable. It is also prone to cause severe 
irritation, folliculitis, regional lymphadenopathy, and staining of skin, clothes, and hair.  
TOPICAL STEROIDS: 
                 Topical steroids are the preferred first choice in the treatment of AA because of 
ease of application, especially in children. The various agents used include Fluocinolone 
acetonide 0.2% cream, 0.1% betamethasone valerate foam, 0.05% betamethasone 
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dipropionate lotion, 0.1% halcinonide, 0.05% clobetasol ointment/foam. The efficacy 
ranges from 28.5 to 61% in various studies depending on the potency of the agent and the 
duration of treatment.21It is recommended to use these drugs 1 cm beyond the affected area. 
Application of topical steroids under occlusion increases the efficacy and also the incidence 
of adverse effects. Folliculitis, telangiectasia, striae, purpura, poor wound healing, 
acneiform eruptions, suppression of HPA axis and skin atrophy are the commonly observed 
side effects. Topical steroids can be applied on alternate days or 5 days a week to prevent 
the local side effects. 
                          Intralesional corticosteroids are the treatment of choice for adults in patchy 
AA. Triamcinolone acetonide is injected into deep dermis or upper subcutaneous tissue 
using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each 
site, once in 4-6 weeks. 10 mg/ml concentration is preferred for scalp and 2.5 mg/ml for 
eye brows and face.22The maximum dose should not be more than 20 mg/sitting. Dermal 
atrophy, Hypopigmentation, telangiectasia can occur. Cataract and glaucoma can occur if 
intralesional corticosteroids are used near the eyebrows. Hair regrowth starts around 4 
weeks with a 60% success rate. 
TOPICAL CALCINEURIN INHIBITORS:  
                      Topical calcinuerin inhibitors act by inhibiting transcription following T-cell 
activation of several cytokines. Topical tacrolimus 0.03% and 0.1% cream and 
Pimecrolimus 0.1% cream were studied for Alopecia areata. They were found ineffective 
in this condition.23,24Cyclosporine , a calcineurin inhibitor is known to cause Hypertrichosis 
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by prolonging the anagen phase of hair cycle. A 10% topical preparation of Cyclosporine 
has been tried for treating Alopecia areata, but the results have not been encouraging. 28 
TOPICAL MINOXIDIL: 
                      Minoxidil causes hair regrowth by stimulating proliferation at the base of the 
bulb and differentiation above the dermal papilla, besides increasing the vascularity to the 
scalp. Some authors have reported good hair regrowth in patients with AA. Minoxidil 5% 
solution is found to be more effective than 2%solution. It is combined with irritants like 
anthralin or dithranol for a better response.25Unwanted facial hair, pruritus and dermatitis 
are the adverse effects observed. Topical minoxidil is found to be ineffective in alopecia 
totalis and universalis. 
CONTACT SENSITISERS: 
 These are potential allergens. The patient is first sensitised to these compounds. By 
repeated application of these compunds, a severe allergic contact dermatitis is induced. 
This causes immunomodulation and gradual regrowth of hair. Happle proposed that the 
contact allergen competes for CD4 cells, attracting them away from the perifollicular 
region (‘antigenic competition’).26Other theories include the stimulation of a local T-
suppressor-cell response and increased expression of TGF-β in the skin, which causes a 
suppression of immune response.  
The agents used include Dinitrochlorobenzene (DNCB), Diphenylcyclopropenone 
(DPCP) and squaric acid dibutyl ester (SADBE). DNCB is found to be mutagenic and is 
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not used these days. Of the other two agents, DPCP is preferred over SADBE as it is 
cheaper and more stable. The efficacy of both the agents is similar at 50-60%. A 2% 
solution of DPCP is made by dissolving 20 mg in 1 ml of acetone. The patient is first 
sensitized with 2% DPCP on a 4 cm 2 area of scalp. It is left on the scalp for 1-2 days to 
sensitise the patient and then washed. The scalp should be protected from the sunlight when 
DPCP is applied. Two weeks later, a very low concentration (0.0001%) of DPCP is applied 
on the same side of scalp and the concentration is increased every week, until a mild 
erythema and pruritus occur. Once the allergic reaction is established, weekly application 
of the same concentration is continued and left for 48 hours. Treatment is continued on the 
same half of the scalp until full regrowth of hair occurs and the second half is treated later. 
Once hair regrowth is stable for more than 3 months, the treatment is gradually tapered 
over a period of 9 months. The commonly seen adverse events include severe dermatitis, 
Cervical/ Occipital lymphadenopathy, Urticaria, Post inflammatory 
hyper/hypopigmentation. Rarely depigmentation and vitiligo can also occur.27 Because of 
potential teratogenicity, these agents are not advised for pregnant and lactating women. 
Before initiating therapy, all the potential outcomes are discussed with the patient and an 
Informed Consent is taken. Personnel handling these agents should wear gloves and protect 
themselves from sensitization. 
OTHER TOPICAL AGENTS:  
Latanoprost and bimatoprost are prostaglandin analogues, used in open angle 
glaucoma and they cause hypertrichosis of eyelashes as an adverse effect. A recent trial 
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shows a cosmetically acceptable eyelash growth in 45% of the latanoprost-treated group.29 
Bimatoprost has also showed cosmetically acceptable eyelash growth in 43.2% of AU 
patients.30 Mild eye irritation and hyperemia are the common side effects noted. 
SYSTEMIC AGENTS: 
                                Systemic agents are used in severe cases of Alopecia areata like 
Alopecia Totalis and Alopecia Universalis. The mainstay of Systemic therapy is 
Corticosteroids. The other drugs are Immunosuppressants, Biologicals and Phototherapy.  
CORTICOSTEROIDS: 
                                Corticosteroids are used in Alopecia areata for their 
immunosuppressive and anti-inflammatory action. Steroids bind to cytosolic receptors and 
mediate lymphocyte transcription and translation. This leads to – 
• Induction of Lymphocyte and Eosinophil apoptosis. 
• Depletion of Langerhans cells in epidermis and dermis. 
• Decreased immunoglobulin synthesis by B cells. 
• Decreased IL-2 production by T cells. 
                     These effects bring about an immunosuppressive action.31 They exert their 
anti-inflammatory effects through the following mechanisms: 
• Stabilisation of lysosomal membranes 
• Blocking the Phospholipases and inhibiting the synthesis of Prostaglandins and                                  
Leukotrienes. 
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• Decreased chemotaxis of proinflammatory cells. 
• Vasoconstriction. 
                   The steroids commonly used for systemic therapy include Prednisolone, 
Methyl prednisolone, Dexamethasone, Betamethasone, Deflazacort etc. They are 
administered as tablets or IV injections. When steroids are used long term, they should not 
be abruptly stopped as they can cause a Rebound Phenomenon. Hence they should be 
gradually tapered. The common adverse effects of Systemic steroids include electrolyte 
disturbances, Hypertension, Diabetes, Osteoporosis, Peptic Ulcer, Exacerbation of a latent 
infection, Psychosis etc. In progressive Alopecia areata, systemic steroids are administered 
as minipulse therapy. 
 
PULSE THERAPY OF STEROIDS: 
                      Pulse therapy refers to the administration of suprapharmacologic doses of 
drugs in an intermittent manner to enhance the therapeutic efficacy and reduce the side 
effects. Pulsed corticosteroid therapy has been proposed as a means of rapidly controlling 
life-threatening or serious conditions with minimal toxicity, allowing for less aggressive 
long term maintenance therapy.32  
                        The selection of drugs and their dosages is arbitrary and based upon cost 
and convenience. Conventionally, methyl predinsolone is the agent most commonly used. 
Pulsed Prednisolone and dexamethasone have made the treatment more affordable and 
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accessible to patients. Steroid pulse therapy is routinely used for conditions like prevention 
of renal graft rejection, lupus nephritis, rheumatoid arthritis, pyoderma gangrenosum, 
pemphigus vulgaris, systemic sclerosis, systemic lupus erythematosus, dermatomyositis, 
toxic epidermal necrolysis, Steven Johnson’s syndrome, sarcoidosis and systemic 
vasculitis. The side effects are less frequent compared to daily corticosteroid therapy. Side 
effects peculiar to steroid pulse therapy include hiccoughs, facial flushing, diarrhoea, 
weakness, joint and muscle pains.33The various pulse regimens used for Alopecia areata 
are- 
a. IV Prednisolone 100mg/day for 3 days in a month repeated for 3 courses.34 
b. Oral Prednisolone 200 mg once a week for 3 months. 
c. 1 g of IV methylprednisolone/day for up to 5 days in a month, repeated for 3 courses. 
                   But all these regimens need admission and clinical and laboratory monitoring. 
Hence minipulse therapy is preferred in Alopecia areata which can be administered in OPD 
setup. 
                  Oral betamethasone given at a dose of 10 mg once weekly is termed as 
minipulse. It is used in dermatoses like vitiligo, lichen planus and alopecia areata with 
variable success rates. 10 mg of betamethasone maybe split into 2 equal doses and given 
as 5 mg/day on 2 consecutive days of a week.32 
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IMMUNOSUPPRESSANTS: 
                               Cyclosporine A causes hypertrichosis in patients because of 
prolongation of anagen phase of hair growth cycle. Its use is limited because of side effects 
and high relapse rate following discontinuation. It is not routinely used in AA.35. In a 
clinical trial Methotrexate showed efficacy in 57% of patients. 36. Azathioprine when given 
at a dose of 2 mg/Kg/day showed regrowth in 53% of patients.37. 
 
PHOTOTHERAPY: 
                              Psoralens+UVA therapy is found to be effective in AA by decreasing 
the perifollicular inflammatory infiltrate. A good response to PUVA is reported in 85% of 
AA patients. PUVA in combination with steroids is found effective in resistant cases of 
AT and AU.38. Mild erythema, burning and increased chance of melanoma are the expected 
side effects. Fractional Erbium YAG laser has shown complete hair regrowth in a patient 
who has not responded to conventional therapies.  
 
BIOLOGICS: 
                     Biologics like infliximab, etanercept, adalimumab, and efalizumab have been 
tried in Alopecia areata but found unsuccessful. Patients reported worsening of AA while 
on treatment. Abatacept has been found to block T-cell activation in mouse models and has 
been proposed for further clinical evaluation in this condition.39 
33 
 
 
CAMOUFLAGE:  
                          Camouflage is mainly needed when regrowth is slow, poor or erratic. 
Hairpieces in the form of wigs, demiwigs, wiglets and cascades are mainly used by women. 
Synthetic hair fibres may be added to the hair to improve thickness. Men may prefer using 
toupees or shaving. In case of AA of eyebrows or eyelashes, tattooing may be the preferred 
camouflage. Camouflage may also be needed by children with Alopecia totalis in whom 
the psychological needs are to be addressed.40 
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STUDY DRUGS 
BETAMETHASONE42, 43 
Betamethasone has a steroid ring, a hydroxyl group attached to the 21 position (21 hydroxy 
steroid) and a fluorine atom attached to it.  
It is a glucocorticoid with minimum mineralocorticoid activity. 
Betamethasone is a white, odorless crystalline powder. It is sparingly soluble in acetone 
and alcohol; slightly soluble in chloroform and ether; and insoluble in water.  
Its chemical name is 9alpha-Fluoro-16beta-methylprednisolone. 
The molecular weight is 392.46 
Its chemical formula is C22H29FO5 and it has the following structure- 
 
                       
                                  Betamethasone 
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Pharmacological action: 
 It exerts anti-inflammatory action by blocking the membrane phospholipases and 
decreasing the production of Leukotrienes and Prostaglandins which mediate 
inflammation.  
 Its immunosuppressive effect is through apoptosis of lymphocytes and by decreasing the 
production of IL-2 which is an immune mediator. 
Pharmacokinetics: 
Absorption: 
o It is well absorbed from GIT.  
o When administered IV, the peak plasma levels are attained at 10-35 minutes. 
Distribution: 
o 64% of drug is protein bound. 
o It has a high volume of distribution of 75-90 L. 
o Plasma half life is 6.5 hours. 
Metabolism: 
o Extensively metabolized in liver to inactive compounds by CYP3A4 
Excretion:  
o Mainly in urine, minimally in bile. 
o Renal clearance: 9.5 mL/min 
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Common Indications:  
The common indications for using Betamethasone include- 
 Adrenocortical Insufficiency       
 Adrenogenital Syndrome 
 Thyroiditis 
 Hypercalcemia           
 Rheumatic Disorders  
 Dermatologic Diseases  
 Allergic Conditions 
 Ocular Disorders 
 Asthma  
 Sarcoidosis   
 Antenatal Use in Preterm Labor  
 Hematologic Disorders 
 Neoplastic Diseases 
 Myasthenia Gravis   
 Organ Transplants   
 Nephrotic and nephritic syndromes 
 Carpal Tunnel Syndrome.     
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Dosage forms: 
It is available as oral tablets, injection for IM and IV use, topical preparations and as 
aerosols for inhalation. 
Tablets are available in 0.5 and 1 mg strengths. 
Adverse effects:  
 Musculoskeletal Effects: Muscle wasting, muscle pain or weakness, delayed wound 
healing, osteoporosis, aseptic necrosis of femoral head. 
 Fluid and Electrolyte Disturbances  
 Ocular Effects: Posterior subcapsular and nuclear cataracts, increased intraocular pressure 
leading to Glaucoma. 
 Anaphylactic reactions: Circulatory collapse, cardiac arrest, bronchospasm.  
 Nervous System Effects: Euphoria, insomnia, mood swings, depression, personality 
changes and aggravation of latent psychoses.  
 Endocrine and Metabolic Effects:  Impaired glucose tolerance, hypercorticism and 
amenorrhea.  
 Immunosuppression 
 Increased Susceptibility to Infection 
Contraindications: 
 Presence of sepsis. 
 Immunosuppressive conditions like HIV and TB  
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 Pregnant and lactating women. 
 To be used with caution in diabetics, hypertensives, epileptics and psychotic patients. 
Drug Interactions:  
 Aminoglutethimide causes loss of corticosteroid-induced adrenal suppression.  
 Macrolides cause a decrease in Betamethasone clearance leading to toxicity.  
 When Betamethasone is administered concomitantly with drugs like amphotericin B or 
diuretics, dangerous hypokalemia may be precipitated.  
 Concomitant use of anticholinesterase agents and Betamethasone may produce severe 
weakness in patients with myasthenia gravis. 
 Coadministration of Betamethasone and warfarin usually results in decrease in response to 
warfarin.  
 Because corticosteroids increase blood glucose concentrations, dosage adjustments of 
antidiabetic agents are required.  
 Serum concentrations of isoniazid is decreased.  
 Cholestyramine increases the clearance of Betamethasone.  
 Increased activity of both cyclosporine and Betamethasone occurs when the two are used 
concurrently leading to convulsions.  
 Patients on digitalis glycosides are at increased risk of arrhythmias due to hypokalemia.  
 Estrogens decrease the hepatic metabolism of Betamethasone, thereby increasing its effect. 
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 Drugs which induce hepatic microsomal drug-metabolizing enzyme activity like 
Phenytoin, Carbamazepine, Rifampicin enhance the metabolism of Betamethasone and 
cause the dosage to be increased. 
  Ketoconazole has been reported to decrease the metabolism of Betamethasone by 60%, 
leading to an increased risk of side effects.  
 Corticosteroids may suppress reactions to skin tests. 
  Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids 
and live or inactivated vaccines due to inhibition of antibody response. 
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HYDROXYCHLOROQUINE42,43 
                               Hydroxychloroquine is an antimalarial drug, which is also being used 
as an antiinflammatory agent in the treatment of rheumatoid arthritis (Disease-Modifying 
Antirheumatic Drug). 
Its chemical name is 2,4,7 -chloroquinolinyl amino pentyl ethylamino ethanol.  
Molecular weight is 335.87. 
 It is available for oral administration as hydroxychloroquine sulfate 200 mg tablet which 
contains 155 mg base.                 
                                 
                                                         Hydroxychloroquine 
Pharmacological actions:  
 Hydroxychloroquine increases lysosomal pH in immune cells leading to decreased release 
of immune mediators. 44 
 It decreases Toll Like Receptor signaling and reduces the activation of dendritic cells and 
the inflammatory process.  
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Pharmacokinetics: 
Absorption: 
 Hydroxychloroquine is readily absorbed from the GI tract.  
 Time taken to achieve peak plasma cncentration is 1 to 3 h.  
Distribution 
 Plasma protein bound 
 Hydroxychloroquine is concentrated in the liver, spleen, kidney, heart, lungs, and brain. 
Metabolism 
 It is partially hepatic. 
 Hydroxychloroquine is metabolised by Cytochrome P450 enzymes (CYP 2D6, 2C8, 3A4 
and 3A5) to N-desethylhydroxychloroquine. 
Elimination 
 50% of the unchanged drug is excreted in urine.  
 Renal excretion is increased by acidification of the urine.  
 The plasma t ½ is approximately 32 days. 
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Indications: 
 Malaria 
 Post lyme arthritis46 
 Systemic lupus erythematosus, Rheumatoid arthritis,  Dermatomyositis, Sjögren's 
syndrome and Porphyria cutanea tarda. 
 Dermatological disorders- Photodermatoses, Lichen planopilaris and other scarring 
alopecias. 
Adverse effects:  
 GIT: Reduced appetite, nausea, vomiting, abdominal cramps and diarrhea. 
 CNS: Headache, nightmares, convulsions, muscle paralysis, weakness or atrophy. 
 SKIN: Worsening of Psoriasis and Porphyria, skin rash, loss of hair, acne. 

 EYE: Macular toxicity (related to the total cumulative dose) and Corneal toxicity (Vortex 
Keratopathy) 45 
 EAR: vertigo, tinnitus, hearing loss. 
 OTHERS: blood disorders, liver failure, itching, Urticaria, loss of weight. 
Contraindications: 
 Pregnant and Lactating women 
 Persons with G6PD deficiency 
 Patients with preexisting retinopathy. 
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OBJECTIVE 
          
To evaluate the efficacy and tolerability of Hydroxychloroquine in the management of 
patients with Alopecia areata compared to weekly oral minipulse therapy with 
Betamethasone. 
PRIMARY ENDPOINT: 
 Percentage regrowth of hair in each quadrant of scalp as estimated using Severity of 
Alopecia Tool. 
SECONDARY ENDPOINT: 
 Improvement in Dermatology Life Quality Index. 
Improvement in Global Assessment Score.  
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METHODOLOGY 
 
                        The study was conducted in patients with Alopecia areata of the scalp, 
attending Outpatient Department of Dermatology, Rajiv Gandhi Government General 
Hospital, Chennai.   
Study design: 
               A randomized, open label, prospective, interventional, comparative study. 
Study population: 
                Adult patients with Alopecia areata of the scalp attending Outpatient 
Department, Department of Dermatology. 
Study center: 
                Institute of Pharmacology, Madras Medical College & Department of 
Dermatology, Rajiv Gandhi Government General Hospital, Chennai. 
Study period: 
August 2014 to July 2015. 
Study duration: 
Treatment period of 12 weeks and      
Post treatment follow up period of 12 weeks per patient.  
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Sample size: 
60 patients (Control group - 30, study group - 30). 
Eligibility criteria: 
 Inclusion criteria:  
 Age: 18 -60 years 
 Sex: Both genders 
 Patients with Alopecia areata of the Scalp region. 
 Patients willing to give written informed consent.  
Exclusion criteria: 
 Pregnant women and lactating mothers 
 Patients with known hypersensitivity to Hydroxychloroquine 
 Patients with visual symptoms or evidence of retinal damage 
 Those who have participated in another clinical study in the last three months  
 Patients with Diabetes mellitus, Hypertension, HIV infection or any other chronic systemic 
illness of liver, kidney, gastrointestinal tract, heart etc.    
Study Procedure: 
                           The study was conducted after obtaining the approval from Institutional 
Ethics Committee, Madras Medical College and it was done in accordance with Good 
Clinical practice (GCP) guidelines.  
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                        Patients diagnosed with Alopecia areata attending the Outpatient 
department, Department of Dermatology, Madras Medical College and Rajiv Gandhi 
Government General Hospital, were explained about the study purpose, procedure and 
benefits of the study. Written informed consent was obtained from those subjects who are 
willing to participate in the study in the prescribed format in regional language. The 
demographic details of the patients were obtained and recorded. 
                      The subjects were screened by complete medical history, clinical 
examination and laboratory investigations. Those who fulfilled the inclusion and exclusion 
criteria were enrolled.  
RANDOMIZATION: 
              The enrolled patients were randomized by simple randomization into either 
control group or study group and received the respective therapy.  
TREATMENT PLAN: 
Control group: 
Tab. Betamethasone 5mg on two consecutive days of the week for 12 weeks. 
 Study group:    
Tab. Hydroxychloroquine 400 mg/day for 12 weeks.    
        After the treatment period of 12 weeks, the drugs were stopped and the patients were 
followed up for a further 12 weeks.       
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STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SCREENING 
ENROLMENT 
TREATMENT PERIOD – 12 WEEKS 
CONTROL GROUP n = 30 
Tab. Betamethasone 10mg/week 
STUDY GROUP n = 30 
Tab. Hydroxychloroquine 400mg/day 
RANDOMIZATION 
STUDY COMPLETION 
STATISTICAL ANALYSIS 
EXCLUSION 
POST TREATMENT FOLLOW UP PERIOD – 12 WEEKS 
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 ASSESSMENT PARAMETERS: 
 Hair regrowth on scalp is assessed using Severity of Alopecia Tool (SALT). 
 The Psychosocial impact of the disease is assessed using Dermatology Life Quality Index 
(DLQI). 
 Outcome of treatment is assessed using Global Assessment (GA). 
SEVERITY OF ALOPECIA TOOL: 47 
SALT score is useful for quantitative assessment of scalp hair loss.  
 The entire scalp is divided into 4 parts based on the surface area,  
Vertex (40% - 0.4), 
Occipital (24% - 0.24),  
Right profile (18% - 0.18), and  
Left profile (18% - 0.18).  
Percentage of hair loss in each area is determined independently and is multiplied by the 
percentage of scalp covered in that area of the scalp, and summing the products of each 
area gives the SALT score.  
For example,  if the hair loss is 40%, 30%, 20% and 10% in top, back and right and left 
side respectively, then the SALT score can be calculated as- (40 × 0.4) + (30 × 0.24) + (20 
× 0.18) + (10 × 0.18) =16 + 7.2 + 3.6 + 1.8 = 28.6.  
51 
 
SALT score is easily reproducible and validated. However, it does not include hair 
pigmentation and nail involvement. Also the loss of hair in other areas of the body cannot 
be assessed. 
DERMATOLOGY LIFE QUALITY INDEX: 48 
                           The Dermatology Life Quality Index is the first dermatology-specific 
quality of life questionnaire. The DLQI consists of 10 questions concerning symptoms and 
feelings, daily activities, leisure, work, and school, personal relationships and treatment 
over the last one week period. Each question is scored from 0 to 3 and the scores summed, 
giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). It is 
designed to be used in adults. 
GLOBAL ASSESSMENT: 
               The treatment outcome and satisfaction level is measured using Global 
Assessment.   The score is given as below- 
A)  Physician 
• Excellent (4) 
• Very good (3) 
• Good (2) 
• Satisfactory (1) 
• No Response (0) 
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B) Patient  
• Excellent (4) 
• Very good (3) 
• Good (2) 
• Satisfactory (1) 
• No Response (0) 
The score is independently given by the physician and patient and the sum is obtained. 
INVESTIGATIONS: 
The following laboratory investigations were performed in the patients on screening and at 
the end of treatment period. 
 Haematology - Haemoglobin, Total leucocyte count. 
 Blood glucose 
 Blood urea 
 Serum creatinine 
 Liver function test (Total Bilirubin, SGOT, SGPT) 
 Ophthalmic examination 
VISIT 1 (Baseline):   
 Written informed consent obtained. 
 Randomization done. 
 Demographic details obtained. 
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 Medical history taken and recorded.  
 Vital signs recorded. 
 SALT, DLQI and GA scores recorded. 
 Laboratory investigations done.  
 Ophthalmic evaluation done          
 Study drugs issued for 4 weeks to respective groups. 
 Patients instructed to report if any adverse events occur.    
Visit 2(At the end of 4 weeks):      
 Vital signs recorded. 
 Patients asked to return empty strips to check compliance. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded. 
 Adverse events monitored. 
 Study medication issued for subsequent 4 weeks.         
Visit 3 (At the end of 8 weeks):   
 Vital signs recorded. 
 Patients asked to return empty strips to check compliance. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded. 
 Adverse events monitored. 
 Study medication issued for subsequent 4 weeks.    
54 
 
Visit 4 (At the end of 12 weeks):   
 Vital signs recorded. 
 Patients asked to return empty strips to check compliance. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded. 
 Adverse events monitored.   
 Lab investigations done.    
 Ophthalmic evaluation done.   
Visit 5 (At the end of 16 weeks):  
 Vital signs recorded. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded. 
Visit 6 (At the end of 20 weeks):  
 Vital signs recorded. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded. 
Visit 7 (At the end of 24 weeks): 
 Vital signs recorded. 
 Clinical examination done.  
 SALT, DLQI and GA scores recorded.  
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Follow up: 
                 The patients were followed up every 4 weeks during the treatment period and 
the post treatment period for assessing the severity of Alopecia areata and for the possibility 
of recurrence of the disease. 
 Adverse events: 
                Patients were advised to report the occurrence of any adverse drug events, other 
illnesses or intake of other drugs. Any adverse event reported by the patient or observed by 
the physician during the study was recorded. The onset of the event, causal relationship to 
the study drug and treatment given were recorded.  
Withdrawal: 
                      During the study period the subject was allowed to withdraw his/her 
voluntary consent and opt out of study. Similarly at the discretion of the investigator, the 
subjects were withdrawn from the study if any serious adverse events occurred. 
Statistical analysis: 
                       The obtained data was analyzed statistically using SPSS software version 
21.0. Distribution of age was analyzed by ANOVA and Sex distribution was analyzed by 
Pearson chi- square test. 
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                       The differences within the groups in SALT score, DLQI score and GA were 
analyzed using students paired t-test. Similarly the differences between the control and test 
groups were analyzed using independent t-test. For the laboratory investigations, the 
differences within the groups before and after treatment were analyzed using student’s 
paired t- test. 
                     p value <0.05 was considered to be statistically significant. 
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RESULTS 
                
                    This study was conducted to assess the efficacy and safety of 
Hydroxychloroquine in comparison with Betamethasone oral minipulse in patients with 
Alopecia areata.   
                      94 patients were screened, of which 28 patients were excluded from the study 
based on selection  criteria and 6 patients who were eligible for the study were not willing 
to participate. 
                    Thereby 60 patients were enrolled in this study. They were randomly allocated 
to one of the 2 groups: Control group [30 patients-Betamethasone] and Study group [30 
patients-Hydroxychloroquine]. All the enrolled patients completed the study. 
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TABLE 1: AGE DISTRIBUTION 
 
 
 
 
 
 
            Table-1 shows the age distribution of patients among the control and study groups.  
Both treatment groups had more patients in 18 to 30 age group. 
FIGURE-1: AGE DISTRIBUTION 
 
                              
                              
                  Figure-1 is the graphical representation of table-1 
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TABLE-2: MEAN AGE DISTRIBUTION 
 
 
 
 
 
  
 
Table-2 shows the Mean Age Distribution of patients among the control and study groups. 
The mean age of patients in control group was 30.3years and in the study group was 
30.5years.   
FIGURE -2 MEAN AGE DISTRIBUTION 
                 
                Figure-2 is a graphical representation of Table-2. 
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TABLE-3: GENDER DISTRIBUTION 
 
 
 
 
 
 
             Table 3 shows the gender distribution in the control and study groups. 
            Percentage of males was higher than females in both the groups. 
 
FIGURE-3: GENDER DISTRIBUTION 
 
                     
                    Figure-3 is the graphical representation of Table-3 
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TABLE-4: NUMBER OF PATCHES OF ALOPECIA AREATA 
 
 
 
 
 
 
Table-4 shows the number of patches of Alopecia areata in both the control and study 
groups. No significant difference was observed between the groups. 
 
FIGURE-4: NUMBER OF PATCHES OF ALOPECIA AREATA 
                 
 
 
       
 
 
 
 
                                             
 
 
               Figure-4 is a graphical representation of Table-4 
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TABLE 5: DURATION OF DISEASE 
 
 
 
 
 
 
 
Table 5 represents the mean duration of the disease. There is no 
significant difference between the control and study groups.                                                    
FIGURE 5: DURATION OF DISEASE 
 
                          
                         Figure 5 is the representation of Table 5 
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 TABLE 6: SCALE OF ALOPECIA TOOL 
 
Table-6 shows mean reduction in hair loss in both the groups by SALT score from baseline 
to week 24. 
Intragroup analysis showed a significant decrease in mean SALT score in both the control 
and study groups from baseline to 24 weeks. Between the groups, the SALT score 
reduction is similar in both the control and study groups from baseline to 16 weeks. At 20 
and 24 weeks, a greater improvement is seen in the control group than the study group. 
                                   
 
 
DURATION 
CONTROL GROUP STUDY GROUP  
P VALUE MEAN S.D MEAN S.D 
0 WEEKS 21.50 11.64 22.37 9.08 0.75 
4WEEKS 19.80 10.31 22.23 8.79 0.33 
8 WEEKS 13.77 6.60 16.6 6.90 0.10 
12 WEEKS 9.17 4.94 9.83 4.71 0.59 
16 WEEKS 8.13 4.45 9.80 4.41 0.15 
20 WEEKS 7.30 4.26 10.0 4.66 0.02 
24 WEEKS 7.47 4.48 10.33 5.38 0.03 
P VALUE 
                   <0.01                   <0.01  
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FIGURE 6: SCALE OF ALOPECIA TOOL 
                                                                          
                      
                          
             Figure 6 is a graphical representation of Table 6. 
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TABLE-7: SALT SCORE AT 12 WEEKS 
GROUPS BASELINE 
 
12 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 21.50 
 
11.643 9.17 4.935 <0.01 
STUDY 22.37 
 
9.076 9.83 4.713 <0.01 
P VALUE 0.749 
 
0.595  
 
Table 7 shows the mean SALT score of control and study groups at baseline and 12 weeks. 
Comparison between the groups shows no significant difference in the mean SALT scores 
at baseline and at 12 weeks. 
TABLE-7A: SALT SCORE AT 24 WEEKS 
 
GROUPS BASELINE 
 
24 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 21.50 
 
11.643 7.47 4.48 <0.01 
STUDY 22.37 
 
9.076 10.33 5.94 <0.01 
P VALUE 0.749 
 
0.029  
 
Table 8 shows the mean SALT score of control and study groups at baseline and 24 weeks.  
Comparison between the groups showed a significant difference in the SALT scores at 24 
weeks. The control group showed a lower SALT score at the end of follow up period when 
compared with the study group. 
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FIGURE-7: SALT SCORE 
               
             
                 Figure 7 is a graphical representations of Table7 and 7A. 
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TABLE 8: DERMATOLOGY LIFE QUALITY INDEX 
 
 
DURATION 
CONTROL GROUP STUDY GROUP  
P VALUE MEAN S.D MEAN S.D 
0 WEEKS 20.07 3.21 20.53 2.66 0.54 
4WEEKS 18.53 3.13 18.87 2.40 0.65 
8 WEEKS 15.10 2.45 15.03 2.57 0.92 
12 WEEKS 11.90 2.63 12.83 2.88 0.19 
16 WEEKS 10.80 2.66 12.23 2.70 0.04 
20 WEEKS 11.13 2.84 13.03 3.03 0.02 
24 WEEKS 11.53 3.41 13.93 3.13 0.006 
P VALUE <0.01 <0.01  
 
Table-8 shows the Dermatology Life Quality Index score in both the control and study 
groups. Within group analysis showed a significant reduction in DLQI scores from 0 to 24 
weeks in both the control and study groups. Analysis between the groups showed that from 
0 to 12 weeks, both the groups showed a comparable score, but from the 16th week 
onwards, the control group showed a significantly better score than the study group. 
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FIGURE 8: DERMATOLOGY LIFE QUALITY INDEX 
 
                         
     
            
                   Figure 8 is a graphical representation of Table 8  
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TABLE-9: DLQI SCORE AT 12 WEEKS 
 
 
Table 9 shows the mean DLQI score of control and study groups at baseline and 12 weeks. 
Comparison between the groups showed no significant difference in the mean DLQI scores 
of the control and study group at baseline and at 12 weeks.                               
TABLE-9A: DLQI SCORE AT 24 WEEKS 
 
Table 9A shows the mean DLQI score of control and study groups at baseline and 24 
weeks.   Comparison between the groups showed no significant difference in the DLQI 
scores at baseline but at 24 weeks, the control group showed a significantly lower score 
than the study group.                                     
                                                  
GROUPS BASELINE 
 
12 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 20.07 
 
3.205 11.90 2.631 <0.01 
STUDY 20.53 
 
2.662 12.83 2.878 <0.01 
P VALUE 0.542 
 
0.195  
GROUPS BASELINE 
 
24 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 20.07 
 
3.205 11.53 3.411 <0.01 
STUDY 20.53 
 
2.662 13.93 3.129 <0.01 
P VALUE 0.542 
 
0.006  
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FIGURE 9: DLQI SCORE 
 
            
 
                Figure 9 is a graphical representations of Table 9 and 9A.      
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TABLE 10: GLOBAL ASSESSMENT 
 
 
DURATION 
CONTROL GROUP STUDY GROUP  
P VALUE MEAN S.D MEAN S.D 
0 WEEKS 1.57 1.14 1.37 1.07 0.49 
4WEEKS 2.7 0.92 2.6 0.81 0.66 
8 WEEKS 4.93 0.79 4.67 0.88 0.22 
12 WEEKS 7.03 0.77 6.7 0.83 0.11 
16 WEEKS 7.23 0.73 6.8 0.99 0.06 
20 WEEKS 6.43 1.14 5.77 1.33 0.04 
24 WEEKS 6.33 1.21 5.6 1.38 0.03 
P VALUE <0.01 <0.01  
 
Table-10 shows the Global Assessment score in both the control and study groups. 
Within group analysis showed a significant increase in GA scores from 0 to 24 weeks in 
both the control and study groups. Analysis between the control and study groups showed 
that from 0 to 16 weeks, both the groups showed a comparable score, but at 20th week and 
24th week, the control group showed a significantly better score than the study group. 
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FIGURE 10: GLOBAL ASSESSMENT 
 
                         
                  
      
      Figure 10 is a graphical representation of Table 10. 
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TABLE-11: GLOBAL ASSESSMENT AT 12 WEEKS 
 
 
Table 11 shows the mean Global assessment score of control and study groups at baseline 
and 12 weeks. Comparison between the groups showed no difference in the mean GA 
scores at baseline, but at 12 weeks the control group showed a significantly higher score 
than the study group. 
TABLE-11A: GLOBAL ASSESSMENT AT 24 WEEKS 
 
 
Table 11A shows the Global assessment score of control and study groups at baseline and 
24 weeks. Comparison reveals a lower score in the study group than the control group. 
                              
 
GROUPS BASELINE 
 
12 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 1.57 
 
1.135 7.08 0.765 <0.01 
STUDY 1.37 
 
1.066 6.50 0.938 <0.01 
P VALUE 0.485 
 
0.019  
GROUPS BASELINE 
 
24 WEEKS  
P VALUE 
MEAN 
 
S.D MEAN S.D 
CONTROL 1.57 
 
1.135 6.33 1.213 <0.01 
STUDY 1.37 
 
1.066 5.60 1.380 <0.01 
P VALUE 0.485 
 
0.033  
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FIGURE 11: GLOBAL ASSESSMENT SCORE 
 
     
 
                  Figure 11 is a graphical representations of Tables 11 and 11A.     
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TABLE-11 A: LABORATORY INVESTIGATIONS (CONTROL GROUP) 
 
 
 
 
INVESTIGATIONS 
CONTROL GROUP  
p-VALUE BASELINE 12 
WEEKS 
HEMOGLOBIN (gm %) 11.68 11.7 0.966 
TOTALWBCCOUNT (cells/mm3) 7423 7520 0.838 
BLOOD SUGAR (mg/dl) 92.13 88.53 0.189 
BLOOD UREA (mg/dl) 25.03 25.8 0.535 
SERUM CREATININE (mg/dl) 0.98 0.94 0.33 
SERUM BILIRUBIN(mg/dl) 0.89 0.82 0.12 
SGOT (IU/L) 29.6 29.4 0.89 
SGPT (IU/L) 28.9 29.7 0.49 
 
Table 11A shows the mean values of laboratory investigations done in the control group 
at the beginning and end of the treatment period. 
 There was no statistically significant difference in the investigation values at baseline and 
12 weeks. 
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TABLE-11 B: LABORATORY INVESTIGATIONS (STUDY GROUP) 
 
 
 
INVESTIGATIONS 
STUDY GROUP  
p-VALUE BASELINE 12 
WEEKS 
HEMOGLOBIN (gm %) 12.03 11.95 0.87 
TOTALWBCCOUNT (cells/mm3) 7847 7070 0.11 
BLOOD SUGAR (mg/dl) 91.67 88.67 0.29 
BLOOD UREA (mg/dl) 24.23 25.93 0.16 
SERUM CREATININE (mg/dl) 0.99 0.96 0.60 
SERUM BILIRUBIN(mg/dl) 0.89 0.86 0.46 
SGOT (IU/L) 29.67 29.20 0.73 
SGPT (IU/L) 28.10 29.37 0.31 
 
Table 11B shows the mean values of laboratory investigations done in the study group at 
the beginning and end of the treatment period. 
There was no statistically significant difference in the investigation values at baseline and 
12 weeks. 
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FIGURE 11A: HAEMOGLOBIN 
 
                
Figure-11A shows the mean haemoglobin in control and study groups at baseline and 12 
weeks                             
FIGURE 11B: TOTAL LEUCOCYTE COUNT 
 
                  
Figure-11B shows mean total WBC count in control and study groups at baseline and 12 
weeks             
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FIGURE 11 C: BLOOD SUGAR 
 
 
 
 
 
 
 
 
 
 
Figure-11C shows the mean blood sugar in control and study groups at baseline and 12 
weeks 
FIGURE 11D: BLOOD UREA 
          
 
Figure-11D shows the mean blood urea in control and study groups at baseline and 12 
weeks 
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FIGURE 11E: SERUM CREATININE 
 
Figure-11E shows the serum creatinine in control and study groups at baseline and 12 
weeks                         
FIGURE 11F: SERUM BILIRUBIN 
     
Figure-11F shows the mean Bilirubin in control and study groups at baseline and 12 weeks 
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FIGURE 11G: SGOT LEVELS 
                          
             
Figure-11G shows the mean SGOT in control and study groups at baseline and 12 weeks. 
FIGURE 11H: SGPT LEVELS 
          
Figure-11H shows the mean SGPT in control and study groups at baseline and 12 weeks                        
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TABLE-12: ADVERSE EVENTS 
 
ADVERSE EVENTS CONTROL 
GROUP 
STUDY 
GROUP 
NAUSEA 1 2 
VOMITING 2 2 
ABDOMEN PAIN  3 4 
MUSCLE PAIN 2 1 
HEAD ACHE 1 1 
DIZZINESS 1 1 
 
Table-12 shows the adverse events noted in both control and study groups. 
Vomiting and abdomen pain were the common adverse events noted during the study. 
Other adverse events noted were nausea, muscle pain, dizziness and headache. 
No difference was noted in the incidence of adverse events between the two groups. 
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FIGURE 12: ADVERSE EVENTS 
 
        
               Figure 12 is a graphical representation of Table 12. 
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TABLE-13: RELAPSES 
 
GROUPS NUMBER OF 
PATIENTS 
 
CONTROL 
 
2 
 
STUDY                                  
 
5 
                  
 Table 13 shows the number of patients who had a relapse. 
More number of patients in study group had a relapse when compared to the control group. 
FIGURE-13: RELAPSES 
 
Figure 13 is a graphical representation of Table 13. 
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  FIGURE 22A&B: TREATMENT PHOTOGRAPHS-CONTROL GROUP    
 
 
     
               
                 Baseline                                                       24 weeks 
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FIGURE 23A&B: TREATMENT PHOTOGRAPHS-STUDY GROUP 
 
 
           
                     Baseline                                                       24 weeks 
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DISCUSSION 
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DISCUSSION 
 
Alopecia areata is a common disorder in our country. All age groups and both sexes 
are equally affected. Even though it is an asymptomatic condition, it causes considerable 
morbidity due to the cosmetic impairment. The course of the disorder is variable and 
prolonged. Although many topical and systemic agents are currently used, they do not offer 
a complete relief for the patient and may lead to distressing adverse events. Presently 
systemic steroids are the mainstay of treatment in a case of severe alopecia areata and 
administered as minipulse. 
  Hydroxychloroquine is an antimalarial agent which is found to have a T cell 
modulating action. Hence it is being used in conditions like Rheumatoid arthritis and 
scarring alopecias. It is also used for systemic photoprotection. Because Alopecia areata is 
a T cell mediated disorder, Hydroxychloroquine may offer a benefit for the patients.  
This study was conducted at the Institute of Pharmacology, Madras Medical 
College, Chennai in collaboration with Department of Dermatology, Rajiv Gandhi 
Government General Hospital, Chennai. 94 patients were screened and 60 patients who 
fulfilled the selection criteria were enrolled for the study. They were randomized into 2 
groups of 30 patients each.                            
Patients in the control group received a standard treatment of Tab. Betamethasone 
5 mg (5 tablets of 1 mg each) on two consecutive days of the week for 12 weeks. Patients 
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in the study group received Tab. Hydroxychloroquine 400mg/day for a period of 12 weeks. 
The patients were assessed every 4 weeks using SALT score, DLQI score and Global 
Assessment.   
Safety and tolerability of the drugs was studied by adverse events monitoring during 
the study period. Laboratory investigations were done at the baseline and at the end of 
study period. In addition, the patients were subjected to ophthalmic evaluation before and 
after treatment. Post treatment follow up was done for an additional period of 12 weeks. 
The data were collected and the results were analysed.  
Basic demographic profile showed no significant difference in the mean age and sex 
distribution in both the control and the study groups. The average age in both the groups 
was 30. More number of male patients were found in both the groups. The number of 
patches and the mean duration of illness were also found to be comparable in both control 
and study groups.  
In this study, the Scale of Alopecia Tool (SALT) score showed a statistically 
significant decrease (p<0.01) at the end of 12 weeks in both the control and study groups. 
This is in agreement with the case series of successful treatment of AA with Tab. 
Hydroxychloroquine. 49,50 Comparison between the groups showed that the improvement 
was similar in both groups during the treatment period, but in the followup period the 
control group treated with Betamethasone maintained the improvement. The study group 
receiving hydroxychloroquine did not maintain the benefits of treatment after 16 weeks. 
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The Dermatology Life Quality Index (DLQI) and Global Assessment (GA) scores 
showed changes similar to the SALT score. Both the groups of patients showed a 
statistically significant improvement in the Quality of Life and overall treatment response 
during the study period. But after stopping the treatment, both groups of patients again 
showed a reduction in response around 16 to 20 weeks which is more pronounced in the 
study group. No significant difference was noted between the groups at the baseline and 
end of study period. 
This study shows that Tab. Hydroxychloroquine 400mg/day is efficacious  in 
the management of patients with Alopecia areata.                                                                                                             
No statistically significant difference in the laboratory parameters like Hemoglobin, 
Total WBC count, Blood Sugar, Blood Urea, Serum Creatinine, Serum SGOT, Serum 
SGPT is noted in the control and study groups at the end of treatment period when 
compared with the baseline using paired t-test. This shows that hydroxychloroquine does 
not affect the lab parameters and has no adverse effect on hepatic and renal functions.  
  No serious adverse events were reported in this study. Abdomen pain and Vomiting 
which were the most common adverse events reported by Khaitan et al for Betamethasone 
were also commonly noted in this study.51Other adverse events noted were nausea, muscle 
pain, dizziness and headache. The patients were asked to take the drugs after food. Other 
adverse events were managed symptomatically. No cases of retinopathy were seen in the 
patients treated with Hydroxychloroquine. No significant difference in the incidence of 
adverse events is noted between the two groups. 
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During the post treatment period, 2 patients from the Betamethasone group and 5 
patients from the Hydroxychloroquine group reported with a relapse of their condition. 
           This study had a 12 weeks treatment period which is an insufficient time to study 
the course and treatment response of a chronic disease. This is an open label study and no 
blinding was done. The assessment parameters were more subjective and prone for 
observer bias. These factors may be considered as the limitations of this study.    
Hydroxychloroquine 400mg/day is found to be efficacious in patients with Alopecia 
areata. As no serious adverse events were reported during the study period, it is concluded 
to be safe in these patients. Further long duration, placebo controlled and blinded clinical 
trials will ascertain its role and usefulness in Alopecia areata. 
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CONCLUSION 
 
From this study, we conclude that, 
 Hydroxychloroquine is efficacious in the management of patients with Alopecia areata. 
 It can be used in those patients in whom systemic steroids are contraindicated. 
 Hydroxychloroquine is well tolerated and not associated with Serious Adverse Events. 
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APPENDIX -I 
 
LIST OF ABBREVIATIONS USED 
 
AA                    - Alopecia areata 
ANOVA           - Analysis of Variance 
AT                    - Alopecia Totalis 
AU                   - Alopecia Universalis 
DLQI                - Dermatology Life Quality Index 
DNCB               - Di Nitro Chloro Benzene 
DPCP                - Diphen Cyclo Propenone 
GA                     -Global Assessment 
HFIP                  - Hair follicle Immune Privilege 
HLA                  - Human Leukocyte Antigen 
IRS                    - Inner Root Sheath 
ORS                  -Outer Root Sheath 
QOL                  - Quality of Life 
MHC                 - Major Histocompatibility Complex 
PUVA               - Psoralens+ Ultraviolet A 
SALT               - Scale of Alopecia Tool 
SADBE           - Squaric Acid Dibutyl Ester 
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                                               APPENDIX -II 
A RANDOMIZED OPEN LABEL COMPARATIVE STUDY OF 
HYDROXYCHLOROQUINE WITH BETAMETHASONE ORAL 
MINIPULSE IN THE MANAGEMENT OF PATIENTS WITH ALOPECIA 
AREATA. 
CASE REPORT FORM 
 
NAME:                                       AGE/SEX       :                PLACE: 
 
OP No:                                        DIAGNOSIS:   
 
 
Inclusion criteria:        YES/NO   
 Age: 18 -60 years 
 Sex: Both genders 
 Patients with Alopecia areata of the Scalp region. 
 Patients willing to give written informed consent. 
 
Exclusion criteria:        YES/NO  
 Pregnant women and lactating mothers 
 Patients with known hypersensitivity to Hydroxychloroquine 
 Patients with visual symptoms or evidence of retinal damage 
 Those who have participated in another clinical study in the last three months  
 Patients with Diabetes mellitus, Hypertension, HIV infection or any other chronic 
systemic illness of liver, kidney, gastrointestinal tract, heart etc.    
Subject: Included/Excluded             Reason if excluded:    
Informed Consent Obtained: Yes/No 
CONTROL/ TEST                         
Subject initials:                 Subject number: 
  
Signature of principal investigator: 
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VISIT 1 
 
1. Vitals: 
 
2. Medical History: 
 
3. Examination: 
4. Investigations: 
 
            Hb:                                    Total WBC count:                                  
 
Blood sugar:                      Blood Urea:                     Serum Creatinine:       
 
Serum Bilirubin                 SGPT:                              SGOT:                               
 
5. Ophthalmic Examination 
 
6. SALT score:                                 DLQI score:                        GA score: 
 
 
VISIT 2 (4 weeks) 
 
1. Vitals: 
 
2. SALT score:                                 DLQI score:                        GA score: 
 
3. Adverse Events: 
 
 
VISIT 3 (8 weeks) 
 
1. Vitals: 
 
2. SALT score:                                 DLQI score:                        GA score: 
 
3. Adverse Events: 
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VISIT 4 (12 weeks) 
 
1. Vitals 
 
2. SALT score:                                 DLQI score:                        GA score: 
 
3. Investigations:  
 
Hb:                                    Total WBC count:                                  
            Blood sugar:                      Blood Urea:                      Serum Creatinine:       
Serum Bilirubin                 SGPT:                               SGOT:                   
                
4. Ophthalmic Examination 
 
5. Adverse Events: 
 
VISIT 5 (16 weeks) 
 
1. Vitals: 
 
2. SALT score:                                 DLQI score:                        GA score: 
 
 
VISIT 6 (20 WEEKS) 
 
      1. Vitals: 
 
      2. SALT score:                                 DLQI score:                        GA score: 
 
 
VISIT 7(24 WEEKS) 
 
1. Vitals: 
 
2. SALT score:                                 DLQI score:                        GA score: 
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                                                                  APPENDIX-III 
PATIENT INFORMATION SHEET 
Title: A RANDOMIZED OPEN LABEL COMPARATIVE STUDY OF 
HYDROXYCHLOROQUINE WITH BETAMETHASONE ORAL MINIPULSE IN 
THE MANAGEMENT OF PATIENTS WITH ALOPECIA AREATA. 
Investigator: 
Name of Participant: 
            This study is conducted in Rajiv Gandhi Govt. General Hospital, Chennai. You are 
invited to take part in this study. The information in this document is meant to help you decide 
whether or not to take part. Please feel free to ask if you have any queries or concerns. 
What is the purpose of this study? 
            Alopecia areata is a common skin problem occuring as hairloss over any part of the 
body. Some cases are very resistant to the available modalities of treatment. We want to 
test the efficacy and safety of treatment with hydroxychloroquine against betamethasone 
in this condition. 
         We have obtained permission from the Institutional Ethics Committee.  
The study design 
            All patients in the study will be divided into 2 groups A & B. You will be assigned 
to either of the groups. Group A receives standard treatment & Group B receives test 
treatment. 
Study Procedures 
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            The study involves evaluation of improvement in your symptoms and rate of hair 
growth.  The planned scheduled visits involve visits at 4th 8th, 12th, 16th, 20th, and 24th weeks 
after your initial visit.  
            At each visit, the study physician will examine you. Blood tests will be carried out 
twice during the study and each time about 15 ml blood will be collected. These tests are 
essential to monitor your condition, and to assess the safety and efficacy of the treatment 
given to you.  
            In addition, if you notice any adverse events, you have to report it. You will be 
required to return unused study medicines when you report for your scheduled visits. This 
will enable correct assessment of the study results. 
Possible benefits to you – Hydroxychloroquine will cause regrowth of hair in alopecia 
areata. 
 Possible benefits to other people - The results of the research may provide benefits to the 
society in terms of advancement of medical knowledge and/or therapeutic benefit to future 
patients.  
Confidentiality of the information obtained from you 
            You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and your 
medical history). By signing this document, you will be allowing the research team 
investigators, other study personnel, sponsors, Institutional Ethics Committee and any 
person or agency required by law like the Drug Controller General of India to view your 
data, if required. The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
             Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken care of 
and you will not lose any benefits to which you are entitled.  
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          The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving any 
reasons. However, it is advisable that you talk to the research team prior to stopping the 
treatment/discontinuing of procedures etc. The results of this study will be informed to you 
at the end of the study. 
 
 
 
Signature of Investigator                                      Signature of Participant  
Date                                                                       Date  
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                                                                   APPENDIX V 
 
INFORMED CONSENT FORM 
 
Title: A RANDOMISED OPEN LABEL COMPARATIVE STUDY OF 
HYDROXYCHLOROQUINE WITH BETAMETHASONE ORAL MINIPULSE IN THE 
MANAGEMENT OF PATIENTS WITH ALOPECIA AREATA. 
Name of the Participant: 
 
I _____________________________ have read the information in this form (or it has been read 
to me). I was free to ask any questions and they have been answered. I am over 18 years of age 
and, exercising my free power of choice, hereby give my consent to be included as a participant in 
this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to give any 
reason and this will not affect my future treatment in this hospital.  
6. I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. 
I understand that they are publicly presented. 
7. I have understand that my identity will be kept confidential if my data are publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document. 
 
 
Name and signature / thumb impression of the participant (or legal representative if participant 
incompetent) 
Name ___________________ Signature_________________ Date_______ 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
Name ______________________ Signature_________________ Date_______ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name _____________________ Signature_________________ Date_______ 
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